Homology Medicines, Inc.

As of February 9, 2024, Homology Medicines, Inc. is rated as "does not qualify" due to being overvalued at $1.53, with a negative price-to-book value of -5.77 and a significant decline of 90.12% against the S&P 500 over the past year, despite a high ROCE of 113.04%.

As of June 10, 2025, the market trend is bearish with moderate strength, supported by bearish signals from moving averages and Bollinger Bands, despite some mixed indicators from MACD and KST.

As of March 2022, the management team of Homology Medicines, Inc. is led by Dr. Arthur Tzianabos as President and CEO, alongside independent directors Mr. Jeffrey Poulton, Mr. Steven Gillis, Dr. Richard Gregory, Dr. Kush Parmar, and Mr. Matthew Patterson.

Homology Medicines, Inc. is a micro-cap genetic medicines company focused on developing gene editing and gene therapy treatments for rare diseases. As of March 2025, it reported a net profit loss of $11 million and has a market cap of $19.73 million.

As of Jun 18, Homology Medicines, Inc. has a market capitalization of 19.73 million, with net sales of 0.00 million and a net profit of -59.79 million over the last four quarters. The company reported shareholder's funds of 5.67 million and total assets of 92.33 million as of Dec 24.